Use of a Recombinant Vaccinia Virus Expressing Interferon Gamma for Post-Exposure Protection against Vaccinia and Ectromelia Viruses

Susan A. Holechek, Karen L. Denzler, Michael C. Heck, Jill Schriewer, R. Mark Buller, Fatema A. Legrand, Paulo H. Verardi, Leslie A. Jones, Tilahun Yilma, Bertram Jacobs

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Post-exposure vaccination with vaccinia virus (VACV) has been suggested to be effective in minimizing death if administered within four days of smallpox exposure. While there is anecdotal evidence for efficacy of post-exposure vaccination this has not been definitively studied in humans. In this study, we analyzed post-exposure prophylaxis using several attenuated recombinant VACV in a mouse model. A recombinant VACV expressing murine interferon gamma (IFN-γ) was most effective for post-exposure protection of mice infected with VACV and ectromelia virus (ECTV). Untreated animals infected with VACV exhibited severe weight loss and morbidity leading to 100% mortality by 8 to 10 days post-infection. Animals treated one day post-infection had milder symptoms, decreased weight loss and morbidity, and 100% survival. Treatment on days 2 or 3 post-infection resulted in 40% and 20% survival, respectively. Similar results were seen in ECTV-infected mice. Despite the differences in survival rates in the VACV model, the viral load was similar in both treated and untreated mice while treated mice displayed a high level of IFN-γ in the serum. These results suggest that protection provided by IFN-γ expressed by VACV may be mediated by its immunoregulatory activities rather than its antiviral effects. These results highlight the importance of IFN-γ as a modulator of the immune response for post-exposure prophylaxis and could be used potentially as another post-exposure prophylaxis tool to prevent morbidity following infection with smallpox and other orthopoxviruses.

Original languageEnglish (US)
Article numbere77879
JournalPLoS One
Volume8
Issue number10
DOIs
StatePublished - Oct 17 2013

Fingerprint

Ectromelia virus
Vaccinia virus
interferon-gamma
Viruses
Interferon-gamma
Post-Exposure Prophylaxis
mice
morbidity
disease control
Smallpox
Infection
Morbidity
infection
Weight Loss
Vaccination
weight loss
Orthopoxvirus
vaccination
Animals
Survival

ASJC Scopus subject areas

  • Agricultural and Biological Sciences(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Use of a Recombinant Vaccinia Virus Expressing Interferon Gamma for Post-Exposure Protection against Vaccinia and Ectromelia Viruses. / Holechek, Susan A.; Denzler, Karen L.; Heck, Michael C.; Schriewer, Jill; Buller, R. Mark; Legrand, Fatema A.; Verardi, Paulo H.; Jones, Leslie A.; Yilma, Tilahun; Jacobs, Bertram.

In: PLoS One, Vol. 8, No. 10, e77879, 17.10.2013.

Research output: Contribution to journalArticle

Holechek, SA, Denzler, KL, Heck, MC, Schriewer, J, Buller, RM, Legrand, FA, Verardi, PH, Jones, LA, Yilma, T & Jacobs, B 2013, 'Use of a Recombinant Vaccinia Virus Expressing Interferon Gamma for Post-Exposure Protection against Vaccinia and Ectromelia Viruses', PLoS One, vol. 8, no. 10, e77879. https://doi.org/10.1371/journal.pone.0077879
Holechek, Susan A. ; Denzler, Karen L. ; Heck, Michael C. ; Schriewer, Jill ; Buller, R. Mark ; Legrand, Fatema A. ; Verardi, Paulo H. ; Jones, Leslie A. ; Yilma, Tilahun ; Jacobs, Bertram. / Use of a Recombinant Vaccinia Virus Expressing Interferon Gamma for Post-Exposure Protection against Vaccinia and Ectromelia Viruses. In: PLoS One. 2013 ; Vol. 8, No. 10.
@article{c938f45dd2b345f7a1da595707937667,
title = "Use of a Recombinant Vaccinia Virus Expressing Interferon Gamma for Post-Exposure Protection against Vaccinia and Ectromelia Viruses",
abstract = "Post-exposure vaccination with vaccinia virus (VACV) has been suggested to be effective in minimizing death if administered within four days of smallpox exposure. While there is anecdotal evidence for efficacy of post-exposure vaccination this has not been definitively studied in humans. In this study, we analyzed post-exposure prophylaxis using several attenuated recombinant VACV in a mouse model. A recombinant VACV expressing murine interferon gamma (IFN-γ) was most effective for post-exposure protection of mice infected with VACV and ectromelia virus (ECTV). Untreated animals infected with VACV exhibited severe weight loss and morbidity leading to 100{\%} mortality by 8 to 10 days post-infection. Animals treated one day post-infection had milder symptoms, decreased weight loss and morbidity, and 100{\%} survival. Treatment on days 2 or 3 post-infection resulted in 40{\%} and 20{\%} survival, respectively. Similar results were seen in ECTV-infected mice. Despite the differences in survival rates in the VACV model, the viral load was similar in both treated and untreated mice while treated mice displayed a high level of IFN-γ in the serum. These results suggest that protection provided by IFN-γ expressed by VACV may be mediated by its immunoregulatory activities rather than its antiviral effects. These results highlight the importance of IFN-γ as a modulator of the immune response for post-exposure prophylaxis and could be used potentially as another post-exposure prophylaxis tool to prevent morbidity following infection with smallpox and other orthopoxviruses.",
author = "Holechek, {Susan A.} and Denzler, {Karen L.} and Heck, {Michael C.} and Jill Schriewer and Buller, {R. Mark} and Legrand, {Fatema A.} and Verardi, {Paulo H.} and Jones, {Leslie A.} and Tilahun Yilma and Bertram Jacobs",
year = "2013",
month = "10",
day = "17",
doi = "10.1371/journal.pone.0077879",
language = "English (US)",
volume = "8",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "10",

}

TY - JOUR

T1 - Use of a Recombinant Vaccinia Virus Expressing Interferon Gamma for Post-Exposure Protection against Vaccinia and Ectromelia Viruses

AU - Holechek, Susan A.

AU - Denzler, Karen L.

AU - Heck, Michael C.

AU - Schriewer, Jill

AU - Buller, R. Mark

AU - Legrand, Fatema A.

AU - Verardi, Paulo H.

AU - Jones, Leslie A.

AU - Yilma, Tilahun

AU - Jacobs, Bertram

PY - 2013/10/17

Y1 - 2013/10/17

N2 - Post-exposure vaccination with vaccinia virus (VACV) has been suggested to be effective in minimizing death if administered within four days of smallpox exposure. While there is anecdotal evidence for efficacy of post-exposure vaccination this has not been definitively studied in humans. In this study, we analyzed post-exposure prophylaxis using several attenuated recombinant VACV in a mouse model. A recombinant VACV expressing murine interferon gamma (IFN-γ) was most effective for post-exposure protection of mice infected with VACV and ectromelia virus (ECTV). Untreated animals infected with VACV exhibited severe weight loss and morbidity leading to 100% mortality by 8 to 10 days post-infection. Animals treated one day post-infection had milder symptoms, decreased weight loss and morbidity, and 100% survival. Treatment on days 2 or 3 post-infection resulted in 40% and 20% survival, respectively. Similar results were seen in ECTV-infected mice. Despite the differences in survival rates in the VACV model, the viral load was similar in both treated and untreated mice while treated mice displayed a high level of IFN-γ in the serum. These results suggest that protection provided by IFN-γ expressed by VACV may be mediated by its immunoregulatory activities rather than its antiviral effects. These results highlight the importance of IFN-γ as a modulator of the immune response for post-exposure prophylaxis and could be used potentially as another post-exposure prophylaxis tool to prevent morbidity following infection with smallpox and other orthopoxviruses.

AB - Post-exposure vaccination with vaccinia virus (VACV) has been suggested to be effective in minimizing death if administered within four days of smallpox exposure. While there is anecdotal evidence for efficacy of post-exposure vaccination this has not been definitively studied in humans. In this study, we analyzed post-exposure prophylaxis using several attenuated recombinant VACV in a mouse model. A recombinant VACV expressing murine interferon gamma (IFN-γ) was most effective for post-exposure protection of mice infected with VACV and ectromelia virus (ECTV). Untreated animals infected with VACV exhibited severe weight loss and morbidity leading to 100% mortality by 8 to 10 days post-infection. Animals treated one day post-infection had milder symptoms, decreased weight loss and morbidity, and 100% survival. Treatment on days 2 or 3 post-infection resulted in 40% and 20% survival, respectively. Similar results were seen in ECTV-infected mice. Despite the differences in survival rates in the VACV model, the viral load was similar in both treated and untreated mice while treated mice displayed a high level of IFN-γ in the serum. These results suggest that protection provided by IFN-γ expressed by VACV may be mediated by its immunoregulatory activities rather than its antiviral effects. These results highlight the importance of IFN-γ as a modulator of the immune response for post-exposure prophylaxis and could be used potentially as another post-exposure prophylaxis tool to prevent morbidity following infection with smallpox and other orthopoxviruses.

UR - http://www.scopus.com/inward/record.url?scp=84885707224&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84885707224&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0077879

DO - 10.1371/journal.pone.0077879

M3 - Article

VL - 8

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 10

M1 - e77879

ER -